ReviewCancer immunology, immunotherapy : CII2021
Combination therapies utilizing neoepitope-targeted vaccines.
Review in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Immunotherapy Treatment of Colorectal Cancer and Lung Metastasis with Genetically Modified Outer Membrane Vesicles Delivering Poly-Neoepitopes in a Mouse Model.Applied biochemistry and biotechnology · 2026Article
- Intra-tumoural microenvironment and bugs-based drug design: foreseeable future in oncology and immuno-oncology.Frontiers in pharmacology · 2026Review
- Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.Experimental hematology & oncology · 2025Review
- Cell-Based Therapies for Solid Tumors: Challenges and Advances.International journal of molecular sciences · 2025Review
- Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer.Cancer immunology research · 2025Review
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- Harnessing antibody-mediated recognition of the intracellular proteome with T cell receptor-like specificity.Frontiers in immunology · 2024Review
- Peptide-based vaccine for cancer therapies.Frontiers in immunology · 2023Review
- Cancer immunotherapies: A hope for the uncurable?Frontiers in molecular medicine · 2023Review
- The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy.Cells · 2022Review
- Development of therapeutic vaccines for the treatment of diseases.Molecular biomedicine · 2022Review
- A synthetic DNA template for fast manufacturing of versatile single epitope mRNA.Molecular therapy. Nucleic acids · 2022Article
- The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy.Journal of biomedical science · 2022Review
- T cell receptor (TCR) signaling in health and disease.Signal transduction and targeted therapy · 2021Review
- TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential.Cancer gene therapy · 2021Review
- Review
- Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.Frontiers in pharmacology · 2021Review
- Neo-Antigen mRNA Vaccines.Vaccines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Clinical successes have been achieved with checkpoint blockade therapy, which facilitates the function of T cells recognizing tumor-specific mutations known as neoepitopes. It is a reasonable hypothesis that therapeutic cancer vaccines targeting neoepitopes uniquely expressed by a patient's tumor would prove to be an effective therapeutic strategy. With the advent of high-throughput next generation sequencing, it is now possible to rapidly identify these tumor-specific mutations and produce therapeutic vaccines targeting these patient-specific neoepitopes. However, initial reports suggest that when used as a monotherapy, neoepitope-targeted vaccines are not always sufficient to induce clinical responses in some patients. Therefore, research has now turned to investigating neoepitope vaccines in combination with other cancer therapies, both immune and non-immune, to improve their clinical efficacies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.